Drug Profile
TAK 428
Alternative Names: TK-428Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Takeda
- Class
- Mechanism of Action Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic neuropathies
Most Recent Events
- 31 Oct 2013 Discontinued - Phase-II for Diabetic neuropathies in European Union (PO)
- 31 Oct 2013 Discontinued - Phase-II for Diabetic neuropathies in USA (PO)
- 29 Jul 2011 Phase-II development in Diabetic neuropathies is ongoing in the US and European Union (PO)